U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07825857) titled 'Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder' on Sept. 11.
Brief Summary: This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the tolerability, safety, and preliminary efficacy of tirzepatide for the treatment of individuals with moderate or severe MtUD. The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD.
Participants will undergo study procedures over 32 weeks, including:
1. completing self-assessments
2. undergo brief physical and review of medical and psychiatric history
3. prov...